Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Safety and efficacy of the fully human IL-12/-23 monoclonal antibody, ABT-874, in the treatment of moderate to severe plaque psoriasis: Results from a Phase II trial

Kimball AB, Gordon KB, Valdes JM. . Safety and efficacy of the fully human IL-12/-23 monoclonal antibody, ABT-874, in the treatment of moderate to severe plaque psoriasis: Results from a Phase II trial. Society for Investigative Dermatology, Annual Meeting, Los Angeles, California. 2007.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.